Executive Overview
In a milestone development for the femtech and precision medicine sectors, women’s health diagnostics company Evvy announced on Tuesday that it has successfully closed a $40 million Series B funding round. The financing was led by Catalio Capital Management, a prominent investment firm focused on biomedical technology and innovative healthcare delivery.
Founded in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro, Evvy has carved out a unique space in the healthcare market by commercializing what it asserts is the world’s only at-home, dual-certified—specifically, CLIA-certified and CLEP-certified—metagenomic next-generation sequencing (mNGS) test. This advanced diagnostic tool is designed to analyze complex vaginal microbiomes utilizing a single, non-invasive swab.
The fresh capital injection comes at a time when the broader healthcare industry is facing a reckoning over systemic gender data gaps. Mainstream AI models, clinical trial frameworks, and diagnostic paradigms have historically bypassed female biology, leaving millions of women to grapple with "unexplained" symptoms, chronic infections, and fertility struggles. Evvy aims to fundamentally rewrite this narrative. By pairing scalable, direct-to-consumer molecular diagnostics with sophisticated artificial intelligence and a rapidly expanding proprietary database, the company is positioning itself at the vanguard of a new era in women’s health—one defined by proactive insights, individualized medicine, and data equity.
Detailed Chronology: From Concept to Clinical Scale
2021: The Genesis of a Movement
Evvy officially burst onto the healthcare scene in July 2021, backed by an initial $5 million seed round led by General Catalyst. The founders—Priyanka Jain (CEO), Laine Bruzek, and Pita Navarro—recognized a glaring blind spot in modern medicine: while the human microbiome had become a focal point of gastrointestinal and dermatological research, the vaginal microbiome remained deeply understudied, despite its profound implications for overall reproductive and systemic health.
The core innovation was simple yet technologically demanding: allow patients to collect a sample at home via a vaginal swab, mail it to a certified laboratory, and receive a comprehensive, molecular-level breakdown of the microbial communities living inside them. Rather than relying on traditional, limited cultures that often fail to capture the full spectrum of bacteria, fungi, and archaea, Evvy leveraged advanced mNGS sequencing to map the entire microbial ecosystem.
2021–2024: Rapid Adoption and Academic Contributions
In the years following its launch, Evvy experienced rapid commercial and scientific expansion. The platform quickly scaled to serve over 100,000 patients across the United States, simultaneously forging partnerships with a network of more than 3,000 forward-thinking clinical practitioners.
Crucially, Evvy did not position itself merely as a direct-to-consumer testing service, but as a translational research engine. Over its first few years of operation, the company generated 15 peer-reviewed publications and abstracts. Through this rigorous academic output, Evvy researchers identified novel bacterial vaginosis (BV) subtypes and discovered hundreds of previously uncatalogued vaginal microbiome genomes, contributing foundational data to a field that has suffered from historical academic neglect.
2024–Present: The AI Integration and Fertility Expansion
As the dataset grew, so did the company’s technological capabilities. In May, Evvy introduced EvvyAI, a proprietary artificial intelligence assistant built specifically to translate complex microbiome sequencing data into actionable, real-time guidance for users while routing complex clinical questions to certified practitioners on the platform.
Most recently, the company announced its strategic expansion beyond routine vaginal health and diagnostics into the fertility sector. Having launched a prospective clinical study leveraging its microbiome tests in IVF clinics last year, Evvy is now actively mapping the correlations between vaginal microbial dysbiosis and complex reproductive hurdles, including infertility, recurrent pregnancy loss, preterm birth, and success rates for assisted reproductive technologies. The $40 million Series B round will serve as the financial catalyst to accelerate these clinical programs, expand the engineering and medical teams, and scale the company’s overarching vision.
Supporting Context & Metrics: The Scale of Femtech Innovation
To understand the weight of Evvy’s Series B raise, one must examine the operational metrics and the macro-environment of the femtech industry:
- Funding Milestone: $40 million Series B led by Catalio Capital Management.
- Patient Reach: Over 100,000 patients served across the United States.
- Clinical Network: Collaborative relationships with roughly 3,000 healthcare practitioners.
- Scientific Output: 15 peer-reviewed publications and abstracts.
- Genomic Discovery: Identification of hundreds of previously uncatalogued vaginal microbiome genomes and novel BV subtypes.
- Competitive Landscape: While Evvy has captured significant market share, the at-home vaginal health and microbiome testing ecosystem also features competitors such as Juno Bio, Tiny Health, and Daye.
Despite the growing presence of these innovative startups, the capital influx into women’s health historically pales in comparison to cardiology or oncology—making a $40 million round led by institutional heavyweights like Catalio a notable bellwether for investor confidence in female-centric biotech.
Official Statements and Industry Insights
In interviews surrounding the funding announcement, CEO and co-founder Priyanka Jain articulated the deeper philosophy driving Evvy’s clinical and technological roadmap.
"When a patient receives their results, they are presented alongside a diagnosis, clinical interpretation, and a clear path of next steps, including personalized prescription care when relevant," Jain noted, emphasizing the company’s commitment to bridging the gap between raw data and clinical utility.
Jain was particularly vocal about the structural flaws embedded within contemporary precision medicine, pointing to the scarcity of high-quality, representative datasets centered on female physiology.
"You can’t build precision medicine for women on datasets that never adequately measured female biology in the first place," Jain stated, referencing recent academic findings demonstrating that leading AI large language models frequently falter when tasked with accurate evaluations of women’s health queries.
Addressing the role of modern computing in overcoming these deficits, Jain added:
"That’s why I believe AI for women’s health needs to be paired with new biological data at scale. AI can help us identify patterns across molecular signals, hormones, symptoms, treatments, fertility outcomes, and other biomarkers that traditional medicine has struggled to connect."
Evvy’s ultimate objective transcends individual diagnostics. By connecting microbiome composition, subjective symptoms, therapeutic interventions, and longitudinal health outcomes, the company is constructing a continuous feedback loop. This architecture is designed not only to refine immediate clinical interventions but also to unearth entirely new biomarkers that have eluded conventional medical research.
Future Outlook: Building the New-Age Pap Smear
Looking toward the horizon, Evvy’s leadership team has set its sights on transforming how systemic women’s health is monitored across the lifespan. The immediate priority involves solidifying the scientific bridges between microbial health and complex reproductive outcomes—moving patients away from demoralizing dead-ends.
"Women shouldn’t have to accept unexplained infertility, unexplained recurrence, or unexplained symptoms as answers when what they often mean is that medicine hasn’t caught up to the data yet," Jain asserted.
In the long term, Evvy’s ambitions are nothing short of revolutionary. Jain envisions the company’s platform evolving into a "new-age Pap smear"—a non-invasive, at-home sampling standard that delivers regular, data-rich insights encompassing infections, chronic inflammation, fertility optimization, PCOS (polycystic ovary syndrome), endometriosis, premenopausal transitions, and HPV progression tracking.
By democratizing access to high-resolution biological data and leveraging artificial intelligence to decode complex molecular interactions, Evvy is challenging the sluggish pace of traditional academic research.
As Jain concluded:
"I don’t think we can wait for traditional research methods to catch up. I believe women, as patients, can be part of pushing the industry forward."
With $40 million in new backing, a rapidly expanding patient cohort, and a growing repository of proprietary genomic data, Evvy is well-equipped to lead that charge.
